Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $68.00 (from $66.00) while maintaining a Buy rating.

The analyst commented: "For 2Q26, Tango recorded net earnings of $0.37 per share vs. our previously estimated net earnings of $0.30 per share. R&D and SG&A expenses were $37.2M and $22.6M, respectively vs. our estimates of $34.9M and $16M. We now project a full-year 2026 net loss of $1.34 per share vs. our prior net loss estimate of $1.14 per share. Tango ended 2Q26 with ~$1B in cash, cash equivalents, and marketable securities, which could provide an operational runway potentially into profitability. After pulling our DCF-based valuation forward, we reiterate our Buy rating and slightly increase our 12-month price target to $68 per share from $66."

You May Also Be Interested In

• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• StubHub Holdings (STUB) PT Lowered to $12 at TD Cowen
• Is the global equity rally broadening? UBS weighs in